Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease.
Level 4 - case-series / case-control
Case-control biomarker study with a small longitudinal case cohort.
PubMed 25342129 · doi:10.1096/fj.14-262048
What was done
Researchers isolated neural-enriched plasma exosomes using immunoabsorption from patients with Alzheimer's disease (AD, n=26), type 2 diabetes (DM2, n=20), frontotemporal dementia (FTD, n=16), and matched controls. Longitudinal samples were also examined from 22 individuals at two time points: when cognitively normal and 1 to 10 years later upon AD diagnosis. ELISA was used to quantify phosphorylated serine 312-IRS-1, P-pan-tyrosine-IRS-1, and their ratio (termed insulin resistance factor, R), followed by stepwise discriminant modeling.
What was found
Exosomal levels of P-serine 312-IRS-1, P-pan-tyrosine-IRS-1, and R were significantly altered in AD and DM2 compared to controls, with R significantly higher in AD than in DM2 or FTD. Discriminant modeling correctly classified 100% of AD, 97.5% of DM2, and 84% of FTD cases. In the longitudinal cohort of 22 patients, marker alterations and R elevations were significantly different from controls 1 to 10 years prior to clinical AD diagnosis. Specific biomarker values and confidence intervals were not reported in the abstract.
Why it matters
The findings show that brain-derived insulin resistance signaling can be measured noninvasively in peripheral blood, suggesting a potential biomarker for identifying preclinical Alzheimer's disease years before symptom onset.
Limits
The study is limited by small sample sizes within each subgroup and a case-control design without an independent validation cohort. Total control numbers, absolute marker concentrations, and diagnostic test characteristics (such as sensitivity and specificity confidence intervals) were not reported in the abstract.
Cited by
- partial Blood biomarkers measuring inactive phosphorylated insulin receptor substrate 1 (IRS-1) can predict Alzheimer's disease diagnosis 10 years in advance with 100% accuracy.